1
Securities and Exchange Commission
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 12, 2001
Biogen, Inc.
(Exact name of Registrant as specified in its charter)
Massachusetts 0-12042 04-3002117
- -------------- ------------ -------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
14 Cambridge Center
Cambridge, MA 02142
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 679-2000
2
ITEM 5. OTHER EVENTS.
On June 12, 2001, the Registrant publicly disseminated a press release
announcing the results of two Phase III clinical trials of its AMEVIVE(TM)
(alefacept) product. The information contained in the press release is
incorporated herein by reference and filed as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
99.1 The Registrant's Press Release dated June 12, 2001.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOGEN, INC.
By: /s/ Thomas J. Bucknum
----------------------------------
Thomas J. Bucknum
Vice President - General Counsel
Date: June 14, 2001
4
EXHIBIT INDEX
Exhibit
Number Description
- ------ -----------
99.1 The Registrant's Press Release dated June 12, 2001